Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iron (III) oxide adipate
- Development stage
- Phase 2
- Lead developer
- Shield Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Iron (III) oxide adipate is an investigational small molecule compound engineered as a phosphate binder for the treatment of hyperphosphataemia, particularly in patients with chronic kidney disease. It is also known as ferric iron oxide adipate and by the code PT20. The drug acts by binding dietary phosphate in the gastrointestinal tract to reduce its absorption and lower serum phosphate levels. This mechanism offers enhanced phosphate-binding properties compared to other available binders[1][5]. Iron (III) oxide adipate has completed Phase 2 clinical trials for hyperphosphataemia[2].
- Other names
- ferric iron oxide adipateCAS 764-65-8CAS764-65-8CAS-764-65-8
Beyond the preview
Go deeper on Iron (III) oxide adipate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iron (III) oxide adipate.